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Complex traumatic events associated with armed conflict, forcible displacement, childhood
sexual abuse, and domestic violence are increasingly prevalent. People exposed to complex
traumatic events are at risk of not only posttraumatic stress disorder (PTSD) but also other
mental health comorbidities. Whereas evidence-based psychological and pharmacological
treatments are effective for single-event PTSD, it is not known if people who have experienced
complex traumatic events can benefit and tolerate these commonly available treatments. Fur-
thermore, it is not known which components of psychological interventions are most effective
for managing PTSD in this population. We performed a systematic review and component net-
work meta-analysis to assess the effectiveness of psychological and pharmacological interven-
tions for managing mental health problems in people exposed to complex traumatic events.
Methods and findings
We searched CINAHL, Cochrane Central Register of Controlled Trials, EMBASE, Interna-
tional Pharmaceutical Abstracts, MEDLINE, Published International Literature on Traumatic
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Stress, PsycINFO, and Science Citation Index for randomised controlled trials (RCTs) and
non-RCTs of psychological and pharmacological treatments for PTSD symptoms in people
exposed to complex traumatic events, published up to 25 October 2019. We adopted a non-
diagnostic approach and included studies of adults who have experienced complex trauma.
Complex-trauma subgroups included veterans; childhood sexual abuse; war-affected; refu-
gees; and domestic violence. The primary outcome was reduction in PTSD symptoms. Sec-
ondary outcomes were depressive and anxiety symptoms, quality of life, sleep quality, and
positive and negative affect. We included 116 studies, of which 50 were conducted in hospi-
tal settings, 24 were delivered in community settings, seven were delivered in military clinics
for veterans or active military personnel, five were conducted in refugee camps, four used
remote delivery via web-based or telephone platforms, four were conducted in specialist
trauma clinics, two were delivered in home settings, and two were delivered in primary care
clinics; clinical setting was not reported in 17 studies. Ninety-four RCTs, for a total of 6,158
participants, were included in meta-analyses across the primary and secondary outcomes;
18 RCTs for a total of 933 participants were included in the component network meta-analy-
sis. The mean age of participants in the included RCTs was 42.6 ± 9.3 years, and 42% were
male. Nine non-RCTs were included. The mean age of participants in the non-RCTs was
40.6 ± 9.4 years, and 47% were male. The average length of follow-up across all included
studies at posttreatment for the primary outcome was 11.5 weeks. The pairwise meta-analy-
sis showed that psychological interventions reduce PTSD symptoms more than inactive
control (k = 46; n = 3,389; standardised mean difference [SMD] = −0.82, 95% confidence
interval [CI] −1.02 to −0.63) and active control (k-9; n = 662; SMD = −0.35, 95% CI −0.56 to
−0.14) at posttreatment and also compared with inactive control at 6-month follow-up (k =
10; n = 738; SMD = −0.45, 95% CI −0.82 to −0.08). Psychological interventions reduced
depressive symptoms (k = 31; n = 2,075; SMD = −0.87, 95% CI −1.11 to −0.63; I2 = 82.7%,
p = 0.000) and anxiety (k = 15; n = 1,395; SMD = −1.03, 95% CI −1.44 to −0.61; p = 0.000)
at posttreatment compared with inactive control. Sleep quality was significantly improved at
posttreatment by psychological interventions compared with inactive control (k = 3; n = 111;
SMD = −1.00, 95% CI −1.49 to −0.51; p = 0.245). There were no significant differences
between psychological interventions and inactive control group at posttreatment for quality
of life (k = 6; n = 401; SMD = 0.33, 95% CI −0.01 to 0.66; p = 0.021). Antipsychotic medicine
(k = 5; n = 364; SMD = –0.45; –0.85 to –0.05; p = 0.085) and prazosin (k = 3; n = 110; SMD =
−0.52; −1.03 to −0.02; p = 0.182) were effective in reducing PTSD symptoms. Phase-based
psychological interventions that included skills-based strategies along with trauma-focused
strategies were the most promising interventions for emotional dysregulation and interper-
sonal problems. Compared with pharmacological interventions, we observed that psycho-
logical interventions were associated with greater reductions in PTSD and depression
symptoms and improved sleep quality. Sensitivity analysis showed that psychological inter-
ventions were acceptable with lower dropout, even in studies rated at low risk of attrition
bias. Trauma-focused psychological interventions were superior to non-trauma-focused
interventions across trauma subgroups for PTSD symptoms, but effects among veterans
and war-affected populations were significantly reduced. The network meta-analysis
showed that multicomponent interventions that included cognitive restructuring and imaginal
exposure were the most effective for reducing PTSD symptoms (k = 17; n = 1,077; mean dif-
ference = −37.95, 95% CI −60.84 to −15.16). Our use of a non-diagnostic inclusion strategy
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may have overlooked certain complex-trauma populations with severe and enduring mental
health comorbidities. Additionally, the relative contribution of skills-based intervention com-
ponents was not feasibly evaluated in the network meta-analysis.
Conclusions
In this systematic review and meta-analysis, we observed that trauma-focused psychologi-
cal interventions are effective for managing mental health problems and comorbidities in
people exposed to complex trauma. Multicomponent interventions, which can include
phase-based approaches, were the most effective treatment package for managing PTSD
in complex trauma. Establishing optimal ways to deliver multicomponent psychological inter-
ventions for people exposed to complex traumatic events is a research and clinical priority.
Author summary
Why was the study done?
• Complex traumatic events are of a multiple or prolonged nature and are increasingly
prevalent owing to unprecedented levels of population displacement, armed conflict,
and increased recognition of childhood sexual abuse and domestic violence.
• People exposed to complex traumatic events are at risk of not only posttraumatic stress
disorder (PTSD) but also other mental health problems.
• There are evidence-based psychological and pharmacological treatments for single-
event PTSD, but it is not known if people who have experienced complex traumatic
events can benefit and tolerate commonly available treatments.
• To inform treatment guidelines and future research, a broad evidence synthesis is
needed that goes beyond existing knowledge to identify candidate interventions for
mental health problems associated with complex trauma.
What did the researchers do and find?
• We undertook a systematic review and meta-analysis of the effectiveness and acceptabil-
ity of psychological and pharmacological treatments for mental health problems in vet-
erans, refugees, victims of childhood sexual abuse and domestic violence, and war-
affected populations.
• We used network meta-analysis to disentangle the relative contribution of different
components of psychological treatments.
• The meta-analysis showed that psychological treatments are effective for treating PTSD,
anxiety, and depression and improving sleep in people with a history of complex trau-
matic events.
• Pharmacological interventions were less effective than psychological interventions for
treating PTSD symptoms and improving sleep.
PLOS MEDICINE Complex trauma and psychological and pharmacological treatments
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003262 August 19, 2020 3 / 34
• Trauma-focused treatments were the most effective approaches, but these treatments
tended to be less effective in veterans and war-affected populations.
• Multicomponent interventions that included two or more components were the most
effective for treating PTSD symptoms, and these approaches were promising for the
management of disturbances of self-organisation.
What do these findings mean?
• Existing evidence-based trauma-focused psychological treatments can be effectively
used as first-line therapy for PTSD and mental health comorbidities in people exposed
to complex trauma.
• Because phasing of treatment was categorised as a constituent part of multicomponent
interventions, there is a case to move beyond binary distinctions of phase-based versus
non-phase-based interventions, which has hampered progress in PTSD research.
• Future studies could test the most effective means to deliver patient-centred and multi-
component interventions for people exposed to complex trauma, especially in those
with higher levels of mental health comorbidity.
Introduction
Complex trauma is an increasing threat to global mental health. Complex trauma is defined as
exposure to multiple or prolonged traumatic events, typically of an interpersonal nature and
from which escape is impossible or difficult. Beyond the prototypical case of childhood sexual
abuse, complex-trauma exposure is also common among those who experience intimate part-
ner violence and conflict. Intimate partner violence accounts for 14% of lifetime traumas and
is associated with a conditional risk of posttraumatic stress disorder (PTSD) of 11.4%; war-
related trauma among military personnel, civilians, and refugees accounts for a further 13.1%
of lifetime trauma exposures and is associated with a conditional risk of PTSD of 3.5% [1].
The burden of mental illness among veterans and forcibly displaced people is of critical
contemporary relevance. Among United Kingdom veterans, PTSD prevalence has increased
from 4% to 6% in the last 10 years and anxiety and depression occur in 31% who held com-
bat roles [2]. UK veterans also report high levels of preservice adversity, and PTSD severity
in this population is associated with childhood adversity [3]. Even higher rates of PTSD and
mental health comorbidities are reported among forcibly displaced people [4]. A record
70.8 million people were displaced at the end of 2018 and the vast proportion seek refuge
and asylum in developing countries with significant implications for health service delivery
and budgets [5].
Individual trauma-focused cognitive behavioural therapy (TF-CBT) and eye movement
desensitisation and reprocessing (EMDR) therapy are effective for reducing clinician-rated
PTSD symptoms [6–8]. Pharmacological treatments are also effective for managing PTSD
symptoms but to a lesser degree [9]. However, treatment adherence and recovery rates can be
low [10]. There is evidence that complexity of trauma exposure is associated with greater num-
ber of different types of comorbid symptoms in addition to PTSD [11, 12], and multiple
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comorbidity of symptoms may contribute to poorer outcome. Indeed, high levels of complex
psychiatric comorbidities may negatively affect treatment outcomes for people with PTSD
[13].
Risk of dropout and reduced treatment efficacy is of particular concern in the presence of
complex PTSD (CPTSD), which has recently been recognised by ICD-11 as a new diagnosis.
CPTSD includes the core symptoms of PTSD (increased anxiety and emotional arousal, avoid-
ance and numbing, reexperiencing the traumatic event) and additional symptoms associated
with disturbances of self-organisation (affective dysregulation, negative self-concept, and
interpersonal problems) [14]. A recent meta-analysis of evidence-based therapies for PTSD
found that a history of childhood trauma was associated with less beneficial outcomes for all
six symptom domains described in CPTSD [15]. These results suggest the importance of
exploring the impact of other types of complex-trauma experiences on symptom outcomes.
Furthermore, we still do not know which treatment components are most effective and accept-
able for people with PTSD following complex-trauma histories.
Because of the narrow analytical focus and limitations of the current evidence base, we con-
ducted a systematic review to identify and integrate all direct and indirect comparisons of psy-
chological and pharmacological treatments versus usual care and active controls in treating
mental health problems in people with a history of complex traumatic events. We present post-
treatment and short-term effectiveness and acceptability results using pairwise meta-analysis
and assessed the relative efficacy of different components of psychological interventions using
component network meta-analysis (NMA).
Methods
The protocol for this study was registered on PROSPERO (CRD42017055523) and can be
found at dx.doi.org/10.17504/protocols.io.bdbni2me. We followed the PRISMA extension
statement for NMAs (S1 Text) [16].
Study design and participants
We included randomised controlled trials (RCTs) and non-RCTs of psychological and/or
pharmacological interventions for adults with a history of complex traumatic events. Follow-
ing independent peer review during the development of the protocol, it was agreed with the
study steering committee that non-RCTs would be included to capture data on emerging treat-
ments and treatments tested in more pragmatic settings. Complex traumatic events were
defined as extreme and prolonged or repetitive in nature and experienced as extremely threat-
ening or horrific and difficult or impossible to escape from [17]. Inclusion was based on the
type of exposure rather than the ICD-11 diagnostic category of CPTSD. Candidate exposures
included (but were not limited to) childhood physical and/or sexual abuse, domestic violence,
forcible displacement, torture, ongoing armed conflict and combat, and human trafficking.
Interventions and comparators
First- or second-line psychological therapies aimed at improving PTSD symptoms and mental
health comorbidities delivered either to individuals or in a group were included. As per our
protocol and in keeping with the classification used by the National Institute for Health and
Care Excellence (NICE) [6], interventions considered were (1) TF-CBT that included one or
more of exposure, cognitive therapy, stress management; (2) EMDR; (3) other psychological
treatments used to treat trauma survivors but that use predominately non-CBT techniques
such as supportive therapy and nondirective counselling, interpersonal psychotherapy (IPT),
hypnotherapy, mindfulness- and compassion-focused therapies, acceptance and commitment
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therapies, accelerated resolution, and sensorimotor therapies. We also included the following
pharmacological interventions: antidepressants (selective serotonin reuptake inhibitors
[SSRIs]; tricyclics and monoamine oxidase inhibitors), antipsychotics (quetiapine, aripipra-
zole, risperidone, olanzapine), hypnotics and anxiolytics (Z-drugs; benzodiazepines; pro-
methazine), alpha blocker and antihypertensive (prazosin), and anticonvulsants (lamotrigine,
topiramate, valproate).
Comparators for psychological interventions were waitlist; treatment as usual (defined as
nonexperimental active treatments that conform to best and/or clinical guideline–recom-
mended care ordinarily made available to patients); no intervention; symptom monitoring;
repeated assessment or other minimal attention control group akin to psychological placebo;
and alternative psychological treatment. Comparators for pharmacological interventions were
placebo; other medication; no intervention; and psychological therapy.
Comparisons of two or more active interventions were included. Differences in compara-
tors were taken into account during data summary and analyses. NMAs were conducted to
provide comparisons of all interventions within a connected network (including comparisons
of active interventions not originally evaluated in included trials).
Outcomes
The primary outcome was reduction in severity of PTSD symptoms as measured using a vali-
dated and standardised clinician-rated scale. Secondary outcomes were reductions in symp-
toms of disturbances of self-organisation (affect dysregulation; negative self-concept;
disturbances in relationships); reduction in symptoms of depression and anxiety, dissociation,
functional somatic syndromes; acceptability (attrition); adverse events and harms from trial
data (e.g., worsening of traumatic stress symptoms); suicidal ideation, attempts, and comple-
tion; and quality of life measured by validated clinician-rated scales. Study outcomes were
measured at posttreatment and/or at the follow-up point defined by the study.
Search strategy and selection criteria
Literature searches were initially conducted in April 2017 in these databases: CINAHL,
Cochrane Central Register of Controlled Trials (CENTRAL), Embase, International Pharma-
ceutical Abstracts, MEDLINE, Published International Literature on Traumatic Stress
(PILOTS), PsycINFO, and Science Citation Index. The search results for each database were
downloaded, imported into EndNote bibliographic software and deduplicated. A full update
search was conducted in August 2018. Finally, update searches using the MEDLINE and Psy-
cINFO databases were carried out in October 2019. Details of search dates, database interfaces,
and the full search strategies used are available from the corresponding author. We did not
restrict on language and translated studies where feasible, but we did not search Chinese data-
bases or translate this language. A sample MEDLINE search is shown in S2 Text.
Studies were eligible if they met these criteria: (1) peer-reviewed original articles; (2) RCTs
and non-RCTs; (3) measured either the primary or one of the candidate secondary outcomes.
The exclusion criteria were (1) reviews/non-original data; (2) dissertations or conference pre-
sentations; (3) complementary and alternative therapeutic interventions that were not under-
pinned by a recognisable psychological focus (i.e., yoga; dance, music, art). To ensure that the
inclusion criteria were consistently applied, a 10% sample of records was first double-screened
based on title and abstract by pairs of researchers. Consensus meetings with the rest of the
research team were held at regular intervals to resolve unclear decisions at the title and abstract
screening phase. Full text records were similarly screened with consensus meetings used to
resolve disagreements.
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Data extraction
Data extraction was piloted on a small sample of studies by three researchers independently.
Both RCTs and non–randomised controlled studies were extracted using the same template
and managed in separate Excel spreadsheets. After consensus checking, included records were
split between three reviewers to singly extract, owing to the volume of evidence. Uncertainties
were resolved by consultation between reviewers tasked with data extraction or by deferring to
the wider review team. Extracted data across domains related to study and participant charac-
teristics and outcomes were compiled in a spreadsheet. Where presented, intention-to-treat
data were extracted instead of complete cases.
Where an included study was published across multiple manuscripts, we used the primary
publication as the main source of information. New and follow-up data were taken from sub-
sequent publications, but the unit of allocation remained the study rather than numbers of
publications.
Risk of bias
Risk of bias for RCTs was assessed with the Cochrane Risk of Bias tool [18]. This tool assessed
each study against domains known to be associated with bias in RCTs: selection, performance,
detection, attrition, reporting, and other bias (which was applied based on the specific con-
text). Each study was assessed as being at either ‘low’, ‘unclear’, or ‘high’ risk of bias across
each of these domains. Attrition bias was used as an independent variable in the sensitivity
analysis; this domain was checked by a further reviewer after all the original appraisals had
been made. Overall, RCTs were classified as having a low risk of bias if none of the domains
were rated as high risk of bias and three or less domains were rated as unclear risk, and RCTs
were classified having a moderate risk of bias if one domain was rated as high risk of bias or if
no domain was rated as high risk of bias but four or more domains were rated as unclear risk.
All other cases were assumed to be at high risk of bias [19].
Studies of non-RCTs were assessed for risk of bias using a modified version of the NICE
(2012) quality appraisal checklist [20]. This checklist was originally developed based on the
Graphic Appraisal Tool for Epidemiological studies (GATE) tool and includes domains of
population bias, allocation, outcomes, and analyses, as well as summary judgements for inter-
nal and external validity [21].
Statistical analysis
Random-effects pairwise meta-analyses were conducted using Stata 15 [22]. Control condi-
tions were grouped into two categories: control (which included waitlist, usual care, no treat-
ment, or other control with no or minimal therapeutic input) and active control (attention
controls or treatment as usual with non–systematic psychological intervention input). Where
multiple intervention groups were included in the study, we analysed the data in the following
way: (1) if one of the groups did not meet criteria for our review, we did not combine across
groups but used data from the group that met our review criteria; (2) where studies included
two intervention groups that met criteria for the same intervention classification, we combined
them together. For example, if a study included a prolonged exposure group and a cognitive
processing therapy group, we combined them together into one group for the TF-CBT
analyses.
Most outcomes were continuous. Where all studies used the same scale, we calculated mean
differences (MDs) and their 95% confidence interval (CI). Where studies used different scales
to measure a particular outcome we calculated standardised MDs (SMDs) and their 95% CI.
In keeping with established cutoffs of effect in behavioural medicine, SMDs of 0.56–1.2 were
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categorised as large, effect sizes of 0.33–0.55 as moderate, and effect sizes of�0.32 as small
[23]. For dichotomous outcomes, such as attrition, we calculated odds ratios (ORs) and their
95% CI. Heterogeneity assessment was based on visual inspection of forest plots and the I2 sta-
tistic [24]. A Q-value (approximating Χ2 distribution) of p< 0.1 indicated statistically signifi-
cant heterogeneity. Statistical heterogeneity was explored using subgroup analyses and
components NMAs.
Given the substantial and inherent heterogeneity expected from our broad research ques-
tions, we conducted a range of subgroup analyses. Firstly, we conducted meta-analyses includ-
ing all psychological interventions vs inactive controls or active controls in all populations.
Secondly, we subgrouped these meta-analyses of all psychological interventions into the fol-
lowing populations based on descriptions in the study and through discussion with clinical
experts: veterans, people who had experienced childhood sexual abuse, refugees, people who
had experienced domestic violence, and war-affected civilians. Thirdly, we subgrouped the
data according to intervention categories commonly reported in the literature based on report-
ing from the original papers and discussion with clinical experts: TF-CBT, EMDR, non-
trauma-focused CBT, mindfulness, dialectical behaviour therapy (DBT), and IPT.
We sought to further explore the impact of different combinations of psychological inter-
vention components using NMAs. We used a Bayesian approach, as this allows greater flexibil-
ity in fitting more complex models and aids exploration of heterogeneity. Given the greater
complexity of the NMA models, we simplified the analyses by focusing on MDs for the Clini-
cian-Administered PTSD Scale in all populations for this outcome.
We fitted models using WinBUGS 1.4.3 based on the components NMAs approach pro-
posed by Welton and colleagues [25] and an adaptation of the WinBUGS code reported by
Freeman and colleagues [26]. The advantages of this approach is that all intervention compo-
nents can be included in the meta-analyses as long as they form a connected network. An
important assumption of the NMA is consistency between direct (i.e., where trials have specifi-
cally compared two or more interventions) and indirect (i.e., data derived from the network
where trials have not directly compared interventions) evidence. To assess the validity of this
assumption, we examined participant and study characteristics and sought input from topic
experts. Based on this assessment, we judged the data similar enough to combine in the NMA.
However, as is common in most NMAs, there was insufficient data to statistically test this
assumption.
All models used a normal likelihood for continuous outcomes and vague priors for treat-
ment effect and between-trial SD. Convergence was assessed based on visual assessment of
trace plots, the Brooks-Gelman-Rubin statistic, and autocorrelation plots using three Markov
chain Monte Carlo chains. All models were judged to have reached convergence after 50,000
iterations. These iterations were then discarded and all results were based on a further 50,000
iterations.
Goodness of fit to the observed data was assessed using total residual deviance and the devi-
ance information criterion (DIC). Total residual deviance approximately equal to the number
of data points was considered to indicate acceptable fit [27]. Greater than five points on the
DIC was considered a substantial difference in goodness of fit between models [28].
We compared four models: (1) Model 1 included the intervention categories used in the
pairwise meta-analyses (TF-CBT, EMDR, non-trauma-focused CBT, mindfulness, and IPT)
compared with either control or active control. (2) Model 2 included all intervention compo-
nents included in the intervention categories from model 1 (support, psychoeducation, relaxa-
tion, cognitive restructuring, in vivo exposure, imaginal exposure, virtual reality exposure,
mindfulness, phase-based). In addition to these, it was also assumed that all active treatments
and attention controls included a placebo component. We also took into account the effect of
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control group (waitlist versus active control). Each component had a separate effect and
assumed the total effect of the intervention was a sum of these separate effects. (3) Model 3
included all intervention components in model 2 plus all available pairs of components. Ten
pairs of intervention components were reported in two or more included studies—support
+ psychoeducation, psychoeducation + relaxation, psychoeducation + cognitive restructuring,
psychoeducation + imaginal exposure, relaxation + mindfulness, relaxation + cognitive
restructuring, relaxation + imaginal exposure, mindfulness + cognitive restructuring, cognitive
restructuring + in vivo exposure, cognitive restructuring + imaginal exposure—and were
therefore included in the analyses. This model allowed for interactions between pairs of inter-
ventions above or below what would be expected from the sum of their components. (4)
Model 4 included all possible combinations of intervention components.
For the attrition outcome, we were concerned that any differences between interventions
and control may be confounded by study design characteristics. Therefore, we conducted sen-
sitivity analyses on attrition outcomes, including only studies with low risk of attrition bias,
and compared these findings with all included studies.
Results
Characteristics of the included studies
A total of 11,845 nonduplicate references were identified by the search (last update 25 October
2019), and 518 full text articles were assessed for eligibility (Fig 1). We included 116 studies
(115 papers) in the systematic review. Of these, 50 were conducted in hospital settings [29–78],
24 were delivered in a community setting [79–102], seven were delivered in military clinics for
veterans or active military personnel [103–109], five were conducted in refugee camps [110–
114], four used remote delivery via web-based or telephone platforms [115–118], four were
conducted in specialist trauma clinics [119–122], two were delivered in home settings [123,
124], and two were delivered in primary care clinics [125, 126]; clinical setting was not
reported in 17 studies [127–143].
Ninety-four (n = 6,158 participants) RCTs were included in meta-analyses across the pri-
mary and secondary outcomes. Eighteen RCTs (n = 933 participants) of psychological inter-
ventions that measured the primary outcome with CAPS were included in the NMA [29, 36,
39, 44, 59, 68, 84, 88, 91–93, 100, 106, 107, 109, 116, 120, 123]. The complex-trauma subgroups
of the included studies were categorised as follows: post–combat deployment veterans (55
studies) [32–35, 37, 39–41, 43–48, 50–54, 56, 58, 60–63, 66–71, 73, 74, 76, 77, 82, 90, 100, 103,
104, 106–108, 115, 116, 121, 123, 124, 127, 128, 132, 133, 136, 143]; war-related (16 studies; 15
papers) [30, 79, 80, 86, 96, 101, 102, 109, 117, 118, 122, 125, 126, 134, 139]; childhood sexual
abuse (17 studies) [36, 38, 49, 55, 57, 59, 72, 84, 91, 95, 97, 98, 129, 135, 141, 142]; refugees (19
studies) [29, 64, 65, 75, 81, 83, 87–89, 94, 99, 110–114, 119, 120, 140]; domestic violence (5
studies) [31, 92, 93, 131, 137]; and mixed presentation (4 studies) [78, 85, 105, 130]. The mean
age of participants in the included RCTs was 42.6 ± 9.3 years, and 42% were male (S1 Table).
Across the 51 (n = 4,018 participants) RCTs of psychological interventions included in the
meta-analyses of the primary outcome, there were 27 comparisons of TF-CBT, nine compari-
sons of EMDR, two comparisons of IPT, three comparisons of mindfulness, three comparisons
of non-trauma-focused CBT, and seven comparisons of DBT. TF-CBT was delivered over a
mean of 10.3 weeks with an average of 1.2 sessions a week, lasting on average 59.4 minutes.
Non-trauma-focused CBT was delivered over a mean of 12 weeks with an average of 1.5 ses-
sions a week for an average of 68.6 minutes. The duration of EMDR was shorter, delivered
over a mean of 5.2 weeks, with an average of 1.1 sessions a week for an average of 61 minutes
each. Mindfulness was delivered over a mean of 6.6 weeks, with an average of 1.1 sessions a
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Fig 1. PRISMA flow diagram.
https://doi.org/10.1371/journal.pmed.1003262.g001
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week lasting an average of 121.6 minutes per session. There was insufficient data to report
mean duration, frequency, and length of sessions for IPT and DBT.
Sixteen (n = 1,233 participants) of 19 RCTs contributed data to meta-analyses of pharmaco-
logical interventions versus placebo. These studies included six comparisons of antidepressants
(of these, four comparisons were of SSRIs), five comparisons of antipsychotics, two compari-
sons of anticonvulsants, and three comparisons of prazosin. Of those studies that compared
SSRIs with a placebo control, there was only sufficient data from trials that tested sertraline
and paroxetine to report mean duration, frequency, and dosing. Sertraline was prescribed for a
mean of 9.5 weeks, to be taken daily, with a mean dose of 50 mg. Paroxetine was prescribed for
a mean of 8.6 weeks, to be taken daily, with a mean dose of 30 mg.
Nine non-RCTs were included, and of these, six reported data for the primary outcome [52,
57, 66, 95, 96, 132–134, 138]. The mean age of participants in the non-RCTs was 40.6 ± 9.4
years, and 47% were male. Effect sizes were calculated for four of these studies (representing
five interventions), as they used inactive control comparators. All comparisons were of
TF-CBT.
Of the 22 RCTs not included in the meta-analyses, five studies compared psychological
interventions in veterans. Of these, two studies compared TF-CBT with present-centred ther-
apy and one study compared mindfulness with present-centred therapy [67, 108]. Addition-
ally, one study compared TF-CBT with exposure alone and another study did not include
extractable data [103]. Two RCTs were identified that compared combined psychological and
pharmacological interventions but included different classes of drugs. Of these, one study was
in veterans and compared phenelzine and psychotherapy with imipramine and psychotherapy
and with psychotherapy alone [90]. A further study was in a mixed population and compared
tianeptine and group therapy with fluoxetine and group therapy [130]. Three RCTs in veterans
that compared pharmacological interventions were not included in the meta-analyses. Of
these, one study compared rivastigmine-augmented therapy with placebo, but there were no
other comparable interventions to combine these data with [127]. Two other studies were
head-to-head comparisons of paroxetine with amitriptyline [35] and of mirtazapine with ser-
traline [37].
Three RCTs in refugees were not meta-analysed. One study compared TF-CBT, supportive
counselling, and psychoeducation and did not include a comparison with a control group
[112]. Another study compared TF-CBT with an exposure-only intervention [65], and one
comparison of TF-CBT with treatment as usual did not include extractable data [75]. Among
RCTs that assessed anxiety in refugees, three studies compared combined psychological and
pharmacological interventions, but no meta-analyses were possible [64, 81, 99]. Additionally,
one RCT in refugees compared paroxetine with sertraline, but this was the only study in this
subgroup that used this comparison, and no meta-analysis was possible [140].
In RCTs among war-affected populations, one study did not report outcomes that were
similar enough with other studies [30], and another study used a head-to-head design that
compared TF-CBT with psychoeducation [79].
Four RCTs in populations with a history of childhood sexual abuse were not included in
meta-analyses. One study attempted to deconstruct how skills training drove the effectiveness
and interacted with counselling and exposure, respectively, and did not offer opportunities to
formally compare outcomes with an inactive or active control group [84]. A head-to-head
design was used by one study to compare analytic group psychotherapy with systemic group
psychotherapy [55], whereas another study combined data from TF-CBT and present-centred
therapy, making it difficult to extract relevant data [38]. A further study that compared
TF-CBT with a minimal attention control group did not include data that could be compared
with other studies [135].
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Risk of bias assessment
Forty, 25, and 42 RCTs were categorised as being of low, moderate, and high risk of bias,
respectively. For RCTs, the risk of bias from random sequence generation was low in 35 (32%)
studies and low for allocation concealment in 12 (11%). Two, four, and three non-RCTs were
categorised as being of low, moderate, and high risk of bias. For non-RCTs, risk of bias associ-
ated with selection bias was low in only two studies (11%). A breakdown of risk of bias by indi-
vidual domains for RCTs is shown in S2 Table and for non-RCTs in S3 Table.
Acceptability
The acceptability sensitivity analysis showed that participants across all populations allocated
to psychological interventions in studies judged to be at low risk of attrition bias were still less
likely to drop out compared with controls (OR = 0.39; 0.21–0.73) than in all studies
(OR = 0.56; 0.40–0.80).
Primary outcome: PTSD symptoms
Effectiveness at posttreatment. The pairwise meta-analysis results for primary and sec-
ondary outcomes across all populations at posttreatment and follow-up versus control are
shown in S4 Table. Across 46 trials in all populations, psychological treatments were effective
at posttreatment in reducing PTSD symptoms in people with a history of complex traumatic
events (Fig 2). Across all populations, TF-CBT, IPT, and EMDR were associated with large
Fig 2. Any psychological treatment for PTSD symptoms versus control at posttreatment across all populations.
The size of the grey box reflects how much weight each study received in the meta-analysis (i.e., the larger the box, the
more this study contributed to the pooled effect represented by the blue diamond). Black bars represent the 95% CI for
the effect size in each study. CI, confidence interval; Cont_N, number in control group; ES, effect size; Int_N, number
in intervention group; PTSD, posttraumatic stress disorder.
https://doi.org/10.1371/journal.pmed.1003262.g002
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treatment effects in favour of the interventions at posttreatment when compared with control
(Fig 3). The 95% CIs for IPT were large, suggesting substantial imprecision. Smaller but still
significant effects were observed at posttreatment when TF-CBT was compared with an active
control (k = 3; n = 447; SMD = −0.30; −0.50 to −0.10; I2 = 13.2%, p = 0.32). There was also evi-
dence from six trials that phase-based interventions that included components to improve
daily functioning as well as trauma-focused therapy were effective at reducing PTSD symp-
toms at posttreatment compared with control. Treatment effects associated with non-trauma-
focused interventions were small and not significant.
Eight trials compared pharmacological interventions with placebo for reducing PTSD
symptoms. Overall, antipsychotic medicine (k = 5; n = 364; SMD = −0.45; −0.85 to −0.05; I2 =
51.2%, p = 0.085) (Fig 4) and prazosin (k = 3; n = 110; SMD = −0.52; −1.03 to −0.02; I2 =
41.4%, p = 0.182) (Fig 5) were effective in reducing PTSD symptoms.
Effectiveness at 6-month follow-up. All psychological treatments were effective com-
pared with control at 6-month follow-up (k = 10; n = 738; SMD = −0.45; −0.82 to −0.08; I2 =
79.4%; p< .001). There was further evidence from four trials that TF-CBT conferred the most
Fig 3. Psychological treatments for PTSD symptoms by intervention category versus control at posttreatment
across all populations. The size of the grey box reflects how much weight each study received in the meta-analysis
(i.e., the larger the box the more this study contributed to the pooled effect represented by the blue diamond). Black
bars represent the 95% CI for the ES in each study. CBT, cognitive behavioural therapy; CI, confidence interval;
Cont_N, number in control group; EMDR, eye movement desensitisation and reprocessing therapy, ES, effect size;
Int_N, number in intervention group; IPT, interpersonal therapy; PTSD, posttraumatic stress disorder.
https://doi.org/10.1371/journal.pmed.1003262.g003
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benefit, with large treatment effects reported at 6-month follow-up (k = 4; n = 206; SMD =
−0.64; −1.10 to −0.18; I2 = 44.9%; p = 0.14).
Subgroup analyses
The pairwise meta-analyses results for the primary outcome by subgroup are presented in S5
Table. It was not possible to conduct meta-analyses for pharmacological interventions by pop-
ulation, as all but one of these studies were conducted in veterans.
Veterans. Among veterans, evidence from 15 trials showed that psychological interven-
tions compared with control were effective at posttreatment for reducing PTSD symptoms,
but the size of the treatment effect was smaller than in the pooled analysis across all popula-
tions. Additionally, unlike the pooled analysis across all populations, these positive effects were
not maintained at 6-month follow-up. However, when compared with an active control in six
trials, psychological interventions were associated with a moderate and significant effect size at
posttreatment (k = 6; n = 260; SMD = −0.40; −0.77 to −0.02; I2 = 48.7%, p = 0.08). Results by
intervention category are shown in Fig 6. In seven trials and four trials, respectively, TF-CBT
Fig 4. Antipsychotics versus placebo for PTSD symptoms at posttreatment. The size of the grey box reflects how
much weight each study received in the meta-analysis (i.e., the larger the box, the more this study contributed to the
pooled effect represented by the blue diamond). Black bars represent the 95% CI for the effect size in each study. CI,
confidence interval; PTSD, posttraumatic stress disorder; SMD, standardised mean difference.
https://doi.org/10.1371/journal.pmed.1003262.g004
Fig 5. Prazosin versus placebo for PTSD symptoms at posttreatment. The size of the grey box reflects how much
weight each study received in the meta-analysis (i.e., the larger the box, the more this study contributed to the pooled
effect represented by the blue diamond). Black bars represent the 95% CI for the effect size in each study. CI,
confidence interval; PTSD, posttraumatic stress disorder; SMD, standardised mean difference.
https://doi.org/10.1371/journal.pmed.1003262.g005
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and EMDR were associated with the largest treatment effect at posttreatment compared with
control, but the effect size was reduced by one-third when compared with the pooled analysis
across all populations. Treatment effects associated with mindfulness favoured the interven-
tion at posttreatment and 6-month follow-up compared with control, but the difference was
not significant in either comparison.
Refugees. Psychological interventions are effective for reducing PTSD symptoms in refu-
gee populations in seven trials at posttreatment and in three trials at 6-month follow-up com-
pared with control. Evidence from two trials showed that TF-CBT conferred the most benefit
at posttreatment compared with control, but the large effects were not maintained in two trials
at 6-month follow-up. EMDR was also associated with large and significant treatment effects
in three trials at posttreatment when compared with control (Fig 7).
Non-trauma-focused CBT was investigated in one non-RCT in a refugee population and
showed a large and significant effect favouring group intervention for reducing PTSD symp-
toms (k = 1; n = 43; SMD = −2.54, −3.21 to −1.88).
Childhood sexual abuse. Across 10 trials, psychological interventions were effective in
reducing PTSD symptoms in childhood sexual abuse populations when compared with control
at posttreatment, but the difference was not significant in three trials that evaluated outcomes
at 6-month follow-up. When broken down by treatment type, only TF-CBT was associated
with positive and significant effects in three trials that compared outcomes at posttreatment
with control (k = 3; n = 153; SMD = −1.22; −2.40 to −0.05; I2 = 90.3%, p = 0.000), but the wide
95% CIs suggest significant imprecision in this estimate.
Fig 6. Psychological treatments for PTSD symptoms by intervention category versus control at posttreatment in
veterans. The size of the grey box reflects how much weight each study received in the meta-analysis (i.e., the larger the
box, the more this study contributed to the pooled effect represented by the blue diamond). Black bars represent the
95% CI for the effect size in each study. CBT, cognitive behavioural therapy; CI, confidence interval; Cont_N, number
in control group; EMDR, eye movement desensitisation and reprocessing therapy; Int_N, number in intervention
group; PTSD, posttraumatic stress disorder; SMD, standardised mean difference.
https://doi.org/10.1371/journal.pmed.1003262.g006
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Evidence from non-RCTs revealed a similar pattern. One study investigated ‘victim to sur-
vivor’ group TF-CBT therapy, and treatment effects were large and favoured the intervention
at posttreatment (k = 1; n = 45; SMD = −1.01; −1.53 to −0.48). Another study examined a mul-
ticomponent trauma-focused intervention delivered in a group format; a small reduction in
PTSD symptoms was found, but this was not significant (k = 1; n = 63; SMD = −0.18; −0.62 to
0.26).
War-related. Evidence from six trials shows that TF-CBT is effective compared with con-
trol at posttreatment in reducing PTSD symptoms in populations affected by war. The size of
the treatment effect was approximately half that observed in the comparable analysis that
pooled data across all populations (Fig 8). Trauma-focused approaches were investigated in
one non-RCT, which showed large treatment effects in favour of the intervention at posttreat-
ment compared with control (k = 1; n = 115; SMD = −1.22; −1.75 to −0.69).
Domestic violence. TF-CBT was the most effective intervention for reducing PTSD
symptoms in people exposed to domestic violence, with large and significant treatment effects
observed across two trials (k = 2; n = 117; SMD = −2.92; −3.45 to −2.39; I2 = 0%, p = 0.970).
Secondary outcomes
The pairwise meta-analyses results for the secondary outcomes by subgroup are presented in
S5 Table. Only outcomes that were meta-analysed are reported.
Disturbances of self-organisation symptoms. Evidence from seven trials showed that
treatment effects favoured psychological interventions for reducing symptoms of emotional
dysregulation compared with control at posttreatment and 6-month follow-up, but the differ-
ences were not significant. Evidence from two trials showed that phase-based interventions
were associated with large treatment effects in favour of reducing interpersonal problems, but
Fig 7. Psychological treatments for PTSD symptoms by intervention category versus control at posttreatment in
refugee populations. The size of the grey box reflects how much weight each study received in the meta-analysis (i.e.,
the larger the box, the more this study contributed to the pooled effect represented by the blue diamond). Black bars
represent the 95% CI for the effect size in each study. CBT, cognitive behavioural therapy; CI, confidence interval;
Cont_N, number in control group; EMDR, eye movement desensitisation and reprocessing therapy; Int_N, number in
intervention group; PTSD, posttraumatic stress disorder; SMD, standardised mean difference.
https://doi.org/10.1371/journal.pmed.1003262.g007
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the difference was not significant. Across five trials, negative self-concept was significantly
improved by any psychological intervention at posttreatment compared with control (k = 5;
n = 215; SMD = 1.81; 0.73–2.89; I2 = 90%, p = 0.000). TF-CBT was associated with large treat-
ment effects at posttreatment compared with control in favour of improving negative self-con-
cept (k = 3; n = 145; SMD = 2.22; 0.75–3.70; I2 = 90.4%, p = 0.000), but the wide 95% CIs
suggest this estimate is potentially imprecise. No studies evaluated the effect of pharmacologi-
cal therapies for these outcomes.
Depression. Across all populations, evidence from 31 and 6 trials respectively showed
psychological interventions are effective for reducing depressive symptoms at posttreatment
and 6-month follow-up when compared with control. Smaller positive effects were seen across
five trials that compared psychological interventions at posttreatment with an active control,
but the difference was not significant (k = 5; n = 473; SMD = −0.38; −0.76 to 0.01; I2 = 70.5%,
p = 0.009). TF-CBT was associated with the most consistently large and significant treatment
effects in favour of reducing depressive symptoms at posttreatment and 6-month follow-up
compared with control; in two trials, TF-CBT was also effective at posttreatment when com-
pared with an active control (k = 2; n = 346; SMD = −0.60; −1.06 to −0.14; I2 = 77.7%,
p = 0.03). In seven trials, EMDR was similarly associated with large and significant treatment
effects for reducing depressive symptoms across all populations when compared with control
at posttreatment; smaller effects were observed in two trials that compared EMDR with an
active control but the difference was not significant (k = 2; n = 72; SMD = −0.32; −1.23 to 0.59;
I2 = 47.8%, p = 0.17). Large and significant effects were observed in two trials that compared
IPT with control at posttreatment across all populations. Similarly, evidence from four trials
showed that phase-based interventions were associated with large and significant treatment
effects at posttreatment when compared with control. Mindfulness was another non-trauma-
based intervention that proved moderately effective for reducing depressive symptoms across
three trials at posttreatment and two trials at 6-month follow-up.
Fig 8. Trauma-focused CBT for PTSD symptoms versus control at posttreatment in war-affected populations.
The size of the grey box reflects how much weight each study received in the meta-analysis (i.e., the larger the box, the
more this study contributed to the pooled effect represented by the blue diamond). Black bars represent the 95% CI for
the ES in each study. CBT, cognitive behavioural therapy; CI, confidence interval; Cont_N, number in control group;
ES, effect size; Int_N, number in intervention group; PTSD, posttraumatic stress disorder.
https://doi.org/10.1371/journal.pmed.1003262.g008
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When broken down by trauma exposure, evidence from three trials showed that TF-CBT is
the most effective trauma-focused intervention for reducing depressive symptoms among vet-
erans, war-affected populations, childhood sexual abuse, refugees, and domestic violence. The
size of the treatment effect among veterans and war-affected populations was attenuated com-
pared with the pooled analysis across all populations at posttreatment compared with control.
Mindfulness was shown to be moderately effective among veterans at posttreatment compared
with control, but this difference was not significant at 6-month follow-up.
Anxiety. Across all populations psychological interventions were shown to be effective in
15 trials for reducing anxiety symptoms at posttreatment compared with control; two trials
contributed evidence that showed that psychological interventions were moderately effective
when compared with an active control (k = 2; n = 346; SMD = −0.44; −0.73 to −0.15; I2 =
46.4%, p = 0.17). For all trauma types, large and significant treatment effects were observed
when TF-CBT and EMDR were compared with control in eight and four trials, respectively.
Among veterans, TF-CBT (k = 3; n = 112; SMD = −1.02; −1.72 to −0.32; I2 = 51%; p = 0.130)
and EMDR (k = 2; n = 44; SMD = −0.91; −2.28 to −0.47; I2 = 77.7%; p = 0.034) were associated
with the largest treatment effects for reducing anxiety symptoms when compared with control
at posttreatment. TF-CBT was also the most effective intervention for reducing anxiety symp-
toms among war-affected populations when compared with control at posttreatment in six
trials.
Quality of life. For all trauma types, small but nonsignificant improvements in quality of
life were observed in six trials that compared all different psychological interventions (k = 6;
n = 406; SMD = −0.33, 95% CI −0.01 to 0.66; I2 = 57.3%; p = 0.021) and four trials that com-
pared TF-CBT with control at posttreatment (k = 4; n = 260; SMD = 0.23, 95% CI −0.33 to
0.79; I2 = 73.9%; p = 0.009).
Sleep quality. Across all trauma types, sleep quality was significantly improved in analyses
of three trials of psychological interventions and two trials of TF-CBT at posttreatment com-
pared with control. Prazosin was the only pharmacological intervention with sufficient data to
conduct meta-analysis. In three trials, prazosin was effective compared with placebo for
improving sleep quality (k = 3; n = 109; SMD = −0.73; −1.12 to −0.34; I2 = 0%, p = 0.486).
Positive and negative affect. Evidence from three trials showed that antipsychotic medica-
tion (all risperidone) was not effective at posttreatment in improving negative (k = 2; n = 284;
SMD = 0.54; 95% CI −0.14 to 1.22; I2 = 0%; p = 0.66) and positive affect (k = 3; n = 329; SMD =
1.75, 95% CI −4.05 to 0.54; I2 = 76.9%; p = 0.01) or general psychopathology symptoms (k = 2;
n = 284; SMD = 0.04, 95% CI −2.08 to 2.16; I2 = 0%; p = 0.43) in people with complex trauma.
Component NMA
We further explored the treatment effects of different psychological components of the included
composite complex interventions by using component NMA. Model 2 had the lowest DIC (262.7,
SD = 8.6). However, model 3 had a comparable DIC and a substantially lower between-study SD
(DIC = 265.5, SD = 6.0), suggesting heterogeneity was better accounted for. The total residual
deviance was also lower in model 3, suggesting a better fit between the model and data. Given
that the difference in DIC was less than three points, we selected model 3 for further analyses.
Fig 9 shows the network plot of combinations of treatment components for the primary
outcome across the 18 studies included in the network [29, 36, 39, 44, 59, 68, 84, 88, 91–93,
100, 106, 107, 109, 116, 120, 123]. MDs for the primary outcome by intervention component
are shown in S6 Table. Interventions that took a multicomponent approach were more effec-
tive than those that did not for reducing PTSD symptoms (k = 17; n = 1,077; MD = −37.95;
−60.84 to −15.16). All these studies included cognitive restructuring and imaginal exposure.
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There was insufficient data to explore interactions between multicomponent approaches and
these intervention components.
Discussion
The findings from this systematic review and meta-analysis suggest that collectively, psycho-
logical interventions are effective for treating PTSD symptoms, treating symptoms of common
mental health problems, and improving sleep across all populations with a history of complex
traumatic events. Evidence from non-RCTs generally supported this finding. These positive
effects were especially pronounced for interventions with a trauma focus, such as TF-CBT and
EMDR, and were observed over the longer term at 6 months and when compared with active
controls. Non-trauma-focused interventions were not generally effective for PTSD symptoms,
with only weak evidence in favour of IPT. There was less good evidence that psychological
interventions were effective for managing the symptom cluster associated with disorders of
self-regulation. We observed that TF-CBT was effective for managing negative self-concept
and phase-based interventions were the leading candidate intervention to address interper-
sonal problems. No interventions were effective for managing emotional dysregulation. These
findings were in the main endorsed by subgroup analyses across different populations exposed
to complex traumatic events. In veteran and war-affected populations, TF-CBT and EMDR
were associated with the greatest reductions in PTSD symptoms and symptoms of depression
and anxiety, but there was a diminution in effect sizes when compared with the results from
the pooled analyses across all populations. Similarly TF-CBT and EMDR were effective for
reducing PTSD symptoms in refugees and populations exposed to childhood sexual abuse,
although the precision of the treatment estimates was more uncertain in the analysis of child-
hood sexual abuse trials. The largest effect sizes were observed in the domestic violence sub-
group analysis, which showed that TF-CBT was effective for managing PTSD symptoms, but
this finding is based on limited evidence. The component NMA showed that multicomponent
interventions that included at least cognitive restructuring and imaginal exposure were the
Fig 9. Network diagram for all combinations of components extracted from included studies (edge thickness
weighted by inverse variance). AC, active control; C, cognitive restructuring; IE, imaginal exposure; IV, in vivo
exposure; M, mindfulness; MU, multidimensional; PE, psychoeducation; R, relaxation; S, support; VR, virtual reality
exposure; WL, waitlist.
https://doi.org/10.1371/journal.pmed.1003262.g009
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most effective for managing PTSD symptoms. Furthermore, analyses indicated that psycholog-
ical interventions were associated with larger effect sizes than pharmacological interventions
for managing PTSD symptoms, symptoms of depression, and sleep at posttreatment. Antipsy-
chotics were shown to be effective for PTSD symptoms, but in the absence of safety data, our
review does not offer findings that might overturn existing clinical practice guidelines that rec-
ommend against the use of risperidone [144]. Prazosin was the only other pharmacological
therapy that conferred modest benefits for PTSD symptoms, and there is scope for revisiting
recommendations against the use of this medication following further studies, especially in
veterans.
These findings partly concur with Merz and colleagues, who recently showed that psycho-
therapeutic treatments are superior to pharmacological treatments for adults with PTSD at last
follow-up but not at end of treatment, reaffirming the view that pharmacological therapy
should not be used as first-line treatment for PTSD [145]. Our findings endorse this view and
extend the relevance of international guideline recommendations that favour using TF-CBT
and EMDR as first-line treatment for PTSD symptoms to those with histories of complex
trauma.
When broken down by trauma exposure, we found a similar patterns of results observed in
the pooled analyses across all populations. TF-CBT and EMDR were the most effective inter-
ventions for PTSD symptoms and common mental health problems for all subgroups. Hetero-
geneity was significantly reduced in the meta-analyses of the primary outcome for
psychological interventions across all subgroups other than childhood sexual abuse. As previ-
ously shown, individual trauma-focused treatments are efficacious for adult survivors of child-
hood sexual abuse with PTSD, albeit analyses have so far failed to unpack which elements of
trauma-focused interventions are most effective [146]. Furthermore, effectiveness of trauma-
focused interventions can be reduced among the most complex cases of childhood sexual
abuse with disturbances of self-organisation [147]. Similarly, previous reviews have shown that
psychosocial interventions, and especially narrative exposure therapy, are effective for PTSD
among refugees in both global and high-income settings [148, 149]. Although our findings
show that trauma-focused interventions are also effective for mental comorbidities as well as
PTSD among refugees, there are still uncertainties about how to practically address mental ill
health among the unprecedented surge in refugees, especially in low-income settings [150].
Significantly, the size and durability of the treatment effects for PTSD and common mental
health problems were diminished among veterans and war-affected populations when com-
pared with the results from the pooled analyses across all populations. Veterans have high
rates of mental comorbidity and experience high levels of problems that can negatively impact
successful engagement with psychological treatment, such as interpersonal problems and emo-
tional dysregulation [151]. Phase-based interventions that seek to address disturbances of self-
organisation through skills-based strategies in combination with strategies that address trau-
matic memories were among the most promising therapeutic approaches for emotional dysre-
gulation and interpersonal problems in veteran and childhood sexual abuse populations.
TF-CBT was the most effective approach for managing negative self-concept. Using combina-
tions of trauma-focused therapies and skills-based strategies in a flexible manner depending
on symptom presentation is likely to be advantageous and removes the need for fixed
approaches in cases of complex trauma [152].
This finding was partly endorsed by the component NMA, which showed that multicompo-
nent interventions that included two or more intervention components are the most effective
for managing PTSD symptoms in people with complex trauma. All effective multicomponent
interventions included imaginal exposure and cognitive restructuring, but this superordinate
group of interventions also included phase-based interventions that combined skills-based
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strategies with trauma-focused strategies. In this sense, phase-based approaches can be
realigned as multicomponent treatments with phasing conceptualised as an intervention com-
ponent rather than a separate intervention category. There is emerging evidence that multi-
component interventions that can be delivered in an integrated or sequenced way and target
more than one outcome are efficacious for people with multiple and often competing health
and behavioural problems [153], including those with complex trauma [154].
Participants were less likely to drop out of psychological treatment than controls, even in
studies judged to be at low risk of attrition bias, suggesting the difference in attrition between
psychological intervention and controls is better explained by acceptability rather than attri-
tion bias. Previously, it has been shown that dropout among active and ex-service military per-
sonnel is higher for TF-CBT than present-centred therapy, especially where prolonged
exposure is used [155]. This has relevance for understanding how acceptability of interventions
and patient preference can inform effective delivery of treatments for people with complex
trauma. Patient preference for psychological interventions is commonly reported [156], but it
is imperative that systems are put in place to ensure people’s preferences are met to maximise
likelihood of improving outcomes [157]. For example, we showed that mindfulness was an
effective treatment for depression among veterans, but optimising delivery of such interven-
tions as part of multicomponent packages needs to be cognisant of patient preferences about
timing, setting, and format [158]. There is scope to explore how established evidence-based
patient-centred frameworks such as the chronic care model can enhance and optimise the
delivery of multicomponent care packages for people with complex trauma. Whereas there is
ample evidence that multifaceted and collaborative care packages are effective for managing
depression and chronic disease in primary care [159, 160], there is only limited evidence that
such patient-centred care approaches are similarly effective for people with PTSD and mental
health comorbidities [161].
Critical to any future research that might underpin patient-centred approaches is the need
to capture outcomes that relate to broader notions about recovery that go beyond clinical
recovery and include improvements in functioning and quality of life. We were only able to
include data from six trials that measured quality of life, but it is well established that people
with PTSD have profound deficits in quality of life and physical limitations, more so than peo-
ple with other anxiety disorders [162]. This is especially true among populations exposed to
complex trauma, such as veterans [163] and war-afflicted civilians [164], who often experience
impairments across multiple life domains, including social and occupational functioning.
Assessment of PTSD-related quality of life should therefore be a priority in the context of trials
to improve the mental health of people exposed to complex trauma.
Additionally, it is important to go beyond assessment of PTSD symptoms and consider broader
psychosocial difficulties that stem from the experience of complex traumatic events. This is espe-
cially true among refugee populations, whose emotional and behavioural problems are often
linked to disruption in psychosocial systems that support mental health. Drawing on the Adapta-
tion and Development After Persecution and Trauma (ADAPT) model, critical psychosocial sys-
tems include safety and security, interpersonal bonds and networks, justice, identities and roles,
and existential meaning [165]. Treatment strategies that embrace the need to counter disruption
to these psychosocial domains might prove effective for promoting a more positive refugee experi-
ence. A recent trial has shown that in refugees from Myanmar, a relatively brief 6-week course of
integrative adapt therapy that is based on the ADAPT model led to improved adaptive capacity
and resilience as well as greater reductions in PTSD symptoms and major depressive disorder
compared with CBT [166]. Although the effect size for PTSD symptoms was smaller in this trial
than those reported in our meta-analyses of psychological interventions among refugees, it might
be that supporting adaptation to the refugee experience is as important as symptom control.
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Strengths and limitations
This review attempted to capture the totality of all controlled evidence about the effectiveness
of psychological and pharmacological treatments for people exposed to complex trauma. We
included non-RCTs on the basis that these studies might include data about novel treatments
delivered in pragmatic settings, but the evidence from these trials was eclipsed by the evidence
from randomised comparisons, which offered the most robust assessments of treatment effec-
tiveness. Our review has a number of strengths that further enhance the robustness of the find-
ings. By taking an approach that favoured inclusion based on trauma exposure rather than
diagnosis, we were able to develop and operationalise broad inclusion criteria for the popula-
tion of interest. In doing so, our search was not tied to a narrowly defined group of studies that
exclusively evaluated interventions in populations with the as yet empirically untested diagnos-
tic label of CPTSD, but rather captured a broader set of studies that addressed mental health
problems in people exposed to complex traumatic events.
Additional strengths of the review include the application of component NMA approaches
to understanding treatment effectiveness and moderators of effectiveness. By searching exten-
sively and adopting a broad approach to inclusion, we were able to assemble a much larger
data set than in previous reviews, enhancing our ability to quantify and explore heterogeneity
and—for the first time, to our knowledge—disentangle the effects of individual components of
composite interventions. NMA offers additional benefits over standard pairwise analyses in
that the comparative efficacy of specific interventions can be estimated and ranked, even when
two treatments have never been compared directly head-to-head. Furthermore, since NMA
can improve the precision of estimates by allowing integration of both direct and indirect
treatment effect estimates, it is recommended over pairwise meta-analyses by the World
Health Organization as a basis for clinical guidelines [167].
Despite using an extensive search strategy and applying broad inclusion criteria, our review
has an underrepresentation of studies with a focus on complex-trauma populations drawn
from prison settings and survivors of torture and forced migrant labour, otherwise known as
modern slavery. Future work should look to identify ways to ensure these populations are not
overlooked. In addition, our search did not capture a critical mass of studies that included out-
comes related to comorbid psychiatric states such as borderline personality disorder. This
might have been offset had we adopted a more clinical and diagnostic approach to our inclu-
sion criteria. Whereas we did include populations with comorbidities, including psychosis and
common mental health problems, we excluded those with dual diagnosis of complex trauma
and substance and alcohol misuse on the grounds that these populations are likely to require
care that is different from and more specialist than that typically provided in the context of
PTSD. However, recent work has shown that treatment-seeking veterans are more likely to
report alcohol dependence and alcohol harm than active military personnel or the general
population, highlighting the need in the future to assess the efficacy of mental health interven-
tions for complex-trauma populations with specific needs [168].
Benefits of treatment can diminish over the longer term, especially in populations exposed
to complex trauma. However, most trials included in this review only reported posttreatment
and short-term outcomes, limiting evaluation of medium- and longer-term outcomes. People
with complex-trauma experiences can benefit over the longer term from psychological thera-
pies, but higher levels of mental health comorbidities are associated with poorer PTSD treat-
ment response [169], suggesting that measurement of important secondary outcomes as well
as PTSD symptoms is critical to understanding longer-term impact of treatments.
There was consistent evidence for the effectiveness of several psychological interventions,
especially TF-CBT and EMDR, for improving PTSD, depression, and anxiety symptoms. Effect
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estimates were lower for pharmacological interventions and lacked precision. However, we
did not make any formal comparisons between psychological and pharmacological interven-
tions either based on direct comparisons in trials or through NMAs, and as such, any informal
comparisons are inherently uncertain. Furthermore, it could be argued that comparisons
about findings from RCTs of psychological versus pharmacological interventions might favour
the former, where blinding may be absent and a control for attention is missing. However,
there is compelling meta-epidemiological evidence that estimated treatment effects do not dif-
fer between trials with and without blinding of patients, healthcare providers, or outcome
assessors [170].
Although we were able to judge the acceptability of interventions, there was insufficient
data to assess harms related to either psychological or pharmacological interventions. Harms
go beyond negative outcomes and refer to enduring negative effects that are directly caused by
the therapy. The absence of harms data is more prevalent for psychological trials than pharma-
cological trials [171], and this is an important omission given that at least 1 in 20 people report
lasting bad effects from psychological treatment [172]. Going forwards, there is a solid case to
collect quantitative data about adverse events and clinically significant worsening of symptoms
during and shortly after treatment, and also qualitative data about patients experience of harm
[173].
The NMA methods used were robust for most intervention components, but credible inter-
vals were wide, indicating very imprecise estimates. This reflects the exploratory nature of the
analyses in which we assessed a number of covariates. In addition, there were insufficient stud-
ies to tease apart the relative contribution of skills-based components, and these were pragmat-
ically classed as multicomponent interventions. Finally, most studies included in the NMA
had small sample sizes and high heterogeneity and were rated at either moderate or high risk
of bias. Therefore, all estimates should be interpreted cautiously.
Conclusion
In conclusion, existing evidence-based psychological trauma-focused interventions are effec-
tive for managing PTSD symptoms and mental health comorbidities in people with complex-
trauma histories. There was less good evidence that pharmacological interventions were effec-
tive for PTSD or mental health comorbidities in the presence of complex-trauma exposure.
Trauma-focused interventions were generally less effective for managing disturbances of self-
organisation as per ICD-11 definitions, with multicomponent interventions showing some
promise for managing these symptom clusters. Overall, multicomponent interventions that
included at least imaginal exposure and cognitive restructuring were the most effective for
managing PTSD symptoms in complex trauma. There is a case for reconceptualising phasing
as an element of multicomponent interventions and for the focus of the research and clinical
community to now develop efficient and effective patient-centred strategies for delivery of
multicomponent treatments for complex trauma.
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